menu
    • menu

    Company profile for Vamsi Labs

    Vamsi Labs-PSE
    News
    Summit, Astrazeneca in Talks Over 15 B Cancer Drug Licensing Deal

    05 Jul 2025

    // REUTERS

    Novartis Drug Cosentyx Fails Late-Stage Trial for Artery Disease

    05 Jul 2025

    // REUTERS

    Alembic Pharma Acquires Utility Therapeutics for $12 Million

    05 Jul 2025

    // INDPHARMAPOST

    DATA COMPILATION
    #PharmaFlow

    Vamsi Labs

    Contact Supplier

    Website

    CPhI South East Asia

    Exhibiting

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Related CompaniesRelated Companies

    About

    Vamsi Labs, established in 1991, is a leading Indian API manufacturer. Specializing in anti-asthmatic, anti-migraine & anti-psychotic APIs, it caters to domestic & international markets(50% sales). Anti-asthma products account for 60% of sales. Vamsi adheres to high corporate governance, transparency, professionalism, & environmental protection standards. It's USFDA & EDQM certified & ISO 9001:2015, ISO 14001:2015, & ISO 45001:2018 certified. With a DSIR-certified R&D Lab, Vamsi continues to innovate & meet the pharma industry's evolving needs. Vamsi is poised to grow its globally while maintaining commitment to excellence and sustainability.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vamsi Labsindia-flag Flag
    Country
    Country
    India
    Address
    Address
    A-14, A-15, A-31, A-32 & A-33, MIDC Area, Chincholi, Solapur - 413255, Maharas...
    Telephone
    Telephone
    +91 2172357274
    Client Email
    Email
    marketing@vamsilabs.com
    Client Website
    Website
    https://www.vamsilabs.com
    Linkedin
    Linkedin
    https://in.linkedin.com/company/vamsi-labs-ltd
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI South East Asia

    Exhibiting

    envelop Contact Supplier

    CPhI South East Asia

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-81553.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-16753.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-42119.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-45814.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Intermediates Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-8460.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    APIs Under Development 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-35681.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    USFDA EIR Letter

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-35388.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2022-2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-58415.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    WHO GMP 2021-2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-86615.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 7804

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

    #PharmaFlow by PHARMACOMPASS
    24 Oct 2024
    Share Share

    USDMF

    read-more
    read-more

    01

    Fluticasone Furoate Ep

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40418

    Submission : 2024-08-26

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Fluticasone Propionate Ep

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40285

    Submission : 2024-08-13

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Haloperidol Usp

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34283

    Submission : 2019-11-14

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Ipratropium Bromide-ep

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40419

    Submission : 2024-08-28

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Tiotropium Bromide Monohydrate

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : Complete

    Rev. Date : 2021-01-11

    Pay. Date : 2020-11-04

    DMF Number : 34808

    Submission : 2020-04-15

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Clenbuterol Hydrochloride Ep

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40283

    Submission : 2024-08-06

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Cyproheptadine Hydrochloride- Ep

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40578

    Submission : 2024-09-30

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Fenoterol Hydrobromide-ep

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40580

    Submission : 2024-09-26

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Formoterol Fumarate Dihydrate Ep

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40450

    Submission : 2024-08-31

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Salbutamol Sulfate- Ep

    India
    arrow
    CPhI South East Asia
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40579

    Submission : 2024-09-30

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Vamsi Labs and get a quotation

    Vamsi Labs is a supplier offers 44 products (APIs, Excipients or Intermediates).

    Find a price of Fluticasone Propionate bulk with DMF, CEP offered by Vamsi Labs

    Find a price of Haloperidol bulk with DMF, CEP offered by Vamsi Labs

    Find a price of Ipratropium Bromide bulk with DMF, CEP offered by Vamsi Labs

    Find a price of Tiotropium Bromide bulk with DMF, CEP offered by Vamsi Labs

    Find a price of Clenbuterol Hydrochloride bulk with CEP offered by Vamsi Labs

    Find a price of Fenoterol Hydrobromide bulk with CEP offered by Vamsi Labs

    Find a price of Formoterol Fumarate bulk with CEP offered by Vamsi Labs

    Find a price of Salmeterol Xinafoate bulk with CEP offered by Vamsi Labs

    Find a price of Fluticasone Furoate bulk with DMF offered by Vamsi Labs

    Find a price of CYPROHEPTADINE HYDROCHLORIDE- EP bulk with DMF offered by Vamsi Labs

    Find a price of CLENBUTEROL HYDROCHLORIDE EP bulk with DMF offered by Vamsi Labs

    Find a price of FENOTEROL HYDROBROMIDE-EP bulk with DMF offered by Vamsi Labs

    Find a price of FORMOTEROL FUMARATE DIHYDRATE EP bulk with DMF offered by Vamsi Labs

    Find a price of SALBUTAMOL SULFATE- EP bulk with DMF offered by Vamsi Labs

    Find a price of SALMETEROL XINAFOATE EP bulk with DMF offered by Vamsi Labs

    Find a price of Budesonide bulk offered by Vamsi Labs

    Find a price of Azelastine Hydrochloride bulk offered by Vamsi Labs

    Find a price of Beclomethasone Dipropionate bulk offered by Vamsi Labs

    Find a price of Ciclesonide bulk offered by Vamsi Labs

    Find a price of Clobetasol Propionate bulk offered by Vamsi Labs

    Find a price of Cyproheptadine Hydrochloride bulk offered by Vamsi Labs

    Find a price of Dexamethasone bulk offered by Vamsi Labs

    Find a price of Dexamethasone Sodium Phosphate bulk offered by Vamsi Labs

    Find a price of Entecavir Monohydrate bulk offered by Vamsi Labs

    Find a price of Glycopyrronium Bromide bulk offered by Vamsi Labs

    Find a price of Glycopyrronium Tosylate bulk offered by Vamsi Labs

    Find a price of Haloperidol Decanoate bulk offered by Vamsi Labs

    Find a price of Haloperidol Lactate bulk offered by Vamsi Labs

    Find a price of Indacaterol Acetate bulk offered by Vamsi Labs

    Find a price of Indacaterol Maleate bulk offered by Vamsi Labs

    Find a price of Levalbuterol Hydrochloride bulk offered by Vamsi Labs

    Find a price of Levalbuterol Sulfate bulk offered by Vamsi Labs

    Find a price of Levalbuterol Tartrate bulk offered by Vamsi Labs

    Find a price of Loperamide Hydrochloride bulk offered by Vamsi Labs

    Find a price of Mometasone Furoate bulk offered by Vamsi Labs

    Find a price of Prednisolone Acetate bulk offered by Vamsi Labs

    Find a price of Procaterol bulk offered by Vamsi Labs

    Find a price of Salbutamol Sulphate bulk offered by Vamsi Labs

    Find a price of Sumatriptan bulk offered by Vamsi Labs

    Find a price of Triamcinolone bulk offered by Vamsi Labs

    Find a price of Triamcinolone Acetonide bulk offered by Vamsi Labs

    Find a price of Tulobuterol Hydrochloride bulk offered by Vamsi Labs

    Find a price of Vilanterol Trifenatate bulk offered by Vamsi Labs

    Find a price of Zoledronic Acid bulk offered by Vamsi Labs

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search